Myd88 Knockout cell line(RAW 264.7)
Catalog Number: KO01225
Price: Online Inquiry
Catalog Number: KO01225
Price: Online Inquiry
Product Information | |
---|---|
Product Name | Myd88 Knockout cell line(RAW 264.7) |
specification | 1*10^6 |
Storage and transportation | Dry ice preservation/T25 live cell transportation. |
Cell morphology | monocyte-like, Adherent cells |
Passage ratio | 1:2-1:3 |
species | Mouse |
Gene | Myd88 |
Gene ID | 17874 |
Build method | Electric rotation method / virus method |
Mycoplasma testing | Negative |
Cultivation system | 90%DMEM+10%FBS |
Parental Cell Line | RAW 264.7 |
Quality Control | Genotype: Myd88 Knockout cell line(RAW 264.7) >95% viability before freezing. All cells were tested and found to be free of bacterial, viruses,mycoplasma and other toxins. |
Gene Information | |
---|---|
Gene Official Full Name | myeloid differentiation primary response gene 88provided by MGI |
Gene Description | Enables ATP-dependent histone chaperone activity; signaling adaptor activity; and signaling receptor binding activity. Involved in several processes, including cellular response to oxidised low-density lipoprotein particle stimulus; positive regulation of macromolecule biosynthetic process; and response to bacterium. Acts upstream of or within several processes, including establishment of endothelial intestinal barrier; regulation of cytokine production; and response to bacterium. Located in cytosol and plasma membrane. Is expressed in several structures, including brain; intestine; and spleen. Used to study Alzheimer's disease; Coronavirus infectious disease; Sjogren's syndrome; and monoclonal gammopathy of uncertain significance. Human ortholog(s) of this gene implicated in colorectal cancer (multiple); hepatocellular carcinoma; lung cancer (multiple); lymphoma (multiple); and primary immunodeficiency disease. Orthologous to human MYD88 (MYD88 innate immune signal transduction adaptor). [provided by Alliance of Genome Resources, Apr 2025] |
Expression | Ubiquitous expression in lung adult (RPKM 14.9), spleen adult (RPKM 14.1) and 28 other tissues See more |
We develop gene knockout solutions tailored to customer requirements and the condition of the target gene.
Cas9 Protein
Cas9 mRNA sgRNA
Cas9 Plasmid
Cas9 Virus
A – Exon KO
gRNAs are designed in the introns flanking the exon, targeting non-multiple-of-3 base deletions in the exon, resulting in frameshift mutations.
B - Frameshift KO
gRNAs are designed within the exon, creating non-multiple-of-3 base deletions to induce frameshift mutations.
C - Complete KO
The entire gene coding sequence is deleted, achieving large-scale knockout effects.
KO Strategy Design
CRISPR Plasmid/Lentiviral Vector Construction
Lentiviral Packaging
Cell Transfection/Lentiviral Infection
Drug Selection
Cell Cryopreservation
Quality Control
Sequencing Validation
Monoclonal Cell Line Generation
Pool Efficiency Validation
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.